Recent Company News

• 02:20 AM ET Jun 15, 2025
  

  Follow-up: Roche announces new dosing restrictions, effective immediately, for Elevidys (CHF 269.70, 0.00)

• 02:06 AM ET Jun 15, 2025
  

  Sarepta provides safety update on ELEVIDYS after second patient death; conference call at 08:00 ET 16-Jun ($36.18, 0.00)

• 05:31 PM ET Jun 09, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 11:05 PM ET Jun 05, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 04:12 PM ET Jun 02, 2025
  

  Roche Holding announces results from Phase III IMforte study of Tecentriq (atezolizumab) in combination with lurbinectedin (Zepzelca) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer at ASCO 2025 (CHF 264.70, 0.00)

• 08:13 AM ET May 23, 2025
  

  European Commission has requested EMA to re-assess the application for Aplidin (€85.30, -2.20)

• 04:08 AM ET May 21, 2025
  

  Chugai Pharmaceutical Phase III study of Tecentriq and Avastin for unresectable hepatocellular carcinoma meets primary endpoint (¥7370.0000, 0)

• 02:45 AM ET May 19, 2025
  

  Chugai Pharmaceutical obtains Japan first approval for Vabysmo for additional indication of treatment of choroidal neovascularization associated with angioid streaks (¥7656.0000, 0)

• 02:39 AM ET May 19, 2025
  

  Chugai Pharmaceutical obtains approval for PiaSky in Taiwan as first subcutaneous treatment for PNH (¥7656.0000, 0)

• 09:04 AM ET May 16, 2025
  

  Sarepta Therapeutics reports new results from study 9001-103 ($35.27, 0.00)